Dihexa is a blood-brain barrier-permeable angiotensin IV analog which exhibits high affinity to HGF with Kd value of 65pM and induces c-Met phosphorylation in the presence of subthreshold concentrations of HGF and augment HGF-dependent cell scattering.

c-Met/RON Dual Kinase Inhibitor is a potent inhibitor against the kinase activities of HGF receptor c-Met and MSP (Macrophage Stimulating Protein) receptor RON with IC50 of 4 and 9 nM, respectively, and it is reported to inhibit NIH3T3 TRP-Met and U-87 tumor growth in mice in vivo in a dose-dependent manner.

JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM.

MK8033 HCl is a specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.

SGX-523 is a potent and selective c-Met inhibitor with IC50 of 4 nM.

AMG-337 is a potent, highly selective and ATP-competitive MET kinase inhibitor with an IC50 of < 5nM in enzymatic assays.

Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].

SAR125844 is a potent and highly selective c-Met inhibitor with potential antineoplastic activity.

INCB28060 is a potent and selective c-MET kinase inhibitor. INCB28060 inhibits c-MET kinase activity with an average IC50 of 0.13 nM.

c-Met Inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.

PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).

Savolitinib is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase (IC50= 5 nM) with potential antineoplastic activity.

EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM, > 200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.

PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM.

LY2801653 is a potent and orally bioavailable inhibitor of c-MET kinase with Ki of 2 nM.

BAY 474 is a tyrosine-protein kinase c-Met inhibitor and a structural genomics consortium (SGC) epigenetics probe.